Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783705 · ClinicalTrials.gov registry record · Phase 2
Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia
A Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT00783705 is a Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 85 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00783705, a Phase 2 study of Non-Small Cell Lung Cancer and Squamous Lung Dysplasia, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. It is not yet known whether inositol is more effective than a placebo in preventing lung cancer in smokers with bronchial dysplasia.
Conditions Studied
Interventions
- OTHER placebo
- DRUG inositol
Study Locations (4)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Minnesota
- Mayo Clinic - Rochester
New Mexico
- Albuquerque Veterans Administration Medical Center - Albuquerque
British Columbia
- BCCA-Vancouver Cancer Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00783705
The ClinicalTrials.gov registry entry for NCT00783705 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (87% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00783705 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Arizona, Minnesota, New Mexico.
Frequently Asked Questions
What is clinical trial NCT00783705 about?
NCT00783705 is a clinical study titled "Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia". This randomized phase II trial is studying inositol to see how well it works compared with a placebo in preventing lung cancer in current or former smokers with bronchial dysplasia. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of inositol may prevent lung cancer. ...
What is the current status of trial NCT00783705?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2014-05.
What conditions does trial NCT00783705 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Squamous Lung Dysplasia.
What interventions are being tested in trial NCT00783705?
The interventions under investigation include: placebo (OTHER), inositol (DRUG).
Who is sponsoring clinical trial NCT00783705?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00783705 being conducted?
This trial has 4 study locations across Arizona, Minnesota, New Mexico, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.